609-537-6363

609-537-6363
MAKE AN APPOINTMENT
  • ADVANCED
    TREATMENTS

Cancer Research at Capital Health

Our Clinical Cancer Trials

Capital Health Cancer Center participates in many National Cancer Institute (NCI), university and pharmaceutical phase II and III clinical trials. Some studies lead to the discovery of new methods to detect and diagnose cancer, while others focus on innovative treatments before they become widely available.

Clinical trials offer patients the very latest in cancer care while giving physicians and researchers the opportunity to study the effectiveness of the treatment. Participation is entirely voluntary.

Our experienced oncologists and clinical research staff carefully review study criteria, potential benefits, risks, and other considerations with eligible patients for enrollment into a clinical study.

Once enrolled, our Clinical Research Department staff carefully monitors patients throughout the research trial and is available to answer questions.

The National Cancer Institute has a brochure “Taking Part in Cancer Treatment Research Studies” to help you understand the details of clinical trials.

To learn more about our ongoing trials for cancer treatment and prevention, please complete the form below and one of our team members will contact you directly! 


Active Clinical Trials Currently Offered:

Neuro Studies

Observation or radiation therapy in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery

  • Study Information: NCT03180268, NCTN# NRG BN003 (https://clinicaltrials.gov/ct2/show/NCT03180268)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

The use of the ketogenic diet as an adjuvant to treatment of glioblastome multiforme

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

  • Study Information: NCT05685004 (https://clinicaltrials.gov/study/NCT05685004)
  • Sponsor: TVAX Biomedical
  • Principal Investigator: Michael Salacz, MD, Director, Medical Neuro-Oncology Program
  • Contact: Office of Clinical Research at 609-394-4130

Comparing the Addition of Radiation Either Before or After Surgery for Patients with Brain Metastases

  • Study Information: NCT05438212 (https://clinicaltrials.gov/study/NCT05438212)
  • Sponsor: NRG Oncology
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

Genetic Testing in Guiding Treatment for Patients with Brain Metastases

  • Study Information: NCT03994796 (https://clinicaltrials.gov/study/NCT03994796)
  • Sponsor: NRG Oncology
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

Liver, Pancreas and GI Studies

GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery 

  • Study Information: NCT05900037 (https://clinicaltrials.gov/study/NCT05900037)
  • Sponsor: GATT Technologies BV
  • Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, HPB Surgeon & Medical Director, Cancer Center
  • Contact: Office of Clinical Research at 609-394-4130

Safety of Cyberknife in Patients With Borderline Respectable or Locally Advanced Pancreatic Adenocarcinoma 

  • Study Information: NCT04998552 (https://clinicaltrials.gov/study/NCT04998552)
  • Sponsor: Capital Health System, Inc.
  • Principal Investigator: Nikhil Thaker, MD, MHA, MBA, PMP, CMQ, FABS, DABR, FAMIA, Medical Director, Radiation Oncology
  • Contact: Office of Clinical Research at 609-394-4130

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) 

  • Study Information: NCT04949256 (https://clinicaltrials.gov/study/NCT04949256)
  • Sponsor: Merck Sharp & Dohme, LLC
  • Principal Investigator: Hongyan Liang, MD, PhD, Medical Oncologist
  • Contact: Office of Clinical Research at 609-394-4130

Circulating Biomarkers and cancer

  • Study Information: N/A
  • Sponsor: Capital Health System, Inc.
  • Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, HPB Surgeon & Medical Director, Cancer Center
  • Contact: Office of Clinical Research at 609-394-4130

Gynecological Studies

A non-randomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers

  • Study Information: NCT04251052, NCTN# CC008 (https://clinicaltrials.gov/ct2/show/NCT04251052)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Joyce Varughese, MD, FACOG, Gynecologic Oncology Surgeon
  • Contact: Office of Clinical Research at 609-394-4130

Lung Studies

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial 

  • Study Information: NCT04402788 (https://clinicaltrials.gov/study/NCT04402788)
  • Sponsor: NCI
  • Principal Investigator: Nikhil Thaker, MD, MHA, MBA, PMP, CMQ, FABS, DABR, FAMIA, Medical Director, Radiation Oncology
  • Contact: Office of Clinical Research at 609-394-4130

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

  • Study Information: NCT04155034 (https://clinicaltrials.gov/study/NCT04155034)
  • Sponsor: SWOG Cancer Research Network
  • Principal Investigator: Nikhil Thaker, MD, MHA, MBA, PMP, CMQ, FABS, DABR, FAMIA, Medical Director, Radiation Oncology
  • Contact: Office of Clinical Research at 609-394-4130

Other Studies

NCI-MATCH: Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma

  • Study Information: NCT02465060, NCTN# EAY131 (https://clinicaltrials.gov/ct2/show/NCT02465060)
  • Sponsor: National Cancer Institute (NCI)
  • Principal Investigator: David Schaebler, MD, Medical Oncologist
  • Contact: Office of Clinical Research at 609-394-4130

Cancer Tissue Biorepository

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Krister Jones, MD, Pathologist, Chief, Cytopathology and Microbiology
  • Contact: Office of Clinical Research at 609-394-4130

Urogenital Studies

Diagnostic Markers in Patients with Bladder Cancer

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with the Blumberg Institute, PA
  • Principal Investigator: Eric Mayer, MD, Urologic Oncology Surgeon, Director, Urologic Robotic Surgery
  • Contact: Office of Clinical Research at 609-394-4130

Stereotactic Body Radiation Therapy or Intesity-Modulated Radiation Therapy in Treating Patients with Stage IIA-B Prostate Cancer

  • Study Information: NCT03367702; NCTN #NRG-GU005 (https://clinicaltrials.gov/ct2/show/NCT03367702)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Timothy Chen, MD, Radiation Oncologist, Medical Director, Stereotactic Radiosurgery
  • Contact: Office of Clinical Research at 609-394-4130

Other resources:

Brain Studies

OBSERVATION OR RADIATION THERAPY IN TREATING PATIENTS WITH NEWLY DIAGNOSED GRADE II MENINGIOMA THAT HAS BEEN COMPLETELY REMOVED BY SURGERY
  • Study Information: NCT03180268, NCTN# NRG BN003 (https://clinicaltrials.gov/ct2/show/NCT03180268)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130
THE USE OF THE KETOGENIC DIET AS AN ADJUVANT TO TREATMENT OF GLIOBLASTOME MULTIFORME
  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
Date added: Sep, 2024
  • Study Information: NCT05685004
  • Collaborator: TVAX Biomedical
  • Principal Investigator: Michael Salacz, MD, Medical Director Neuro-Oncology
  • Contact: Office of Clinical Research at 609-394-4133
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
  • Study Information: NCT05438212
  • Collaborator: NRG Oncology
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4134
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Date added: Sep, 2024
  • Study Information: NCT03994796
  • Collaborator: Alliance for Clinical Trials in Oncology
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4135

Liver and Pancreas Studies

CIRCULATING BIOMARKERS AND CANCER
  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with the Blumberg Institute, PA
  • Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, Hepato-pancreato-biliary Surgeon, Medical Director, Capital Health Cancer Center
  • Contact: Office of Clinical Research at 609-394-4130
Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma
Date added: May, 2023
  • Study Information: NCT04998552
  • Sponsor: Capital Health System, Inc.
  • Principal Investigator: Shirnett Williamson, MD, Medical Director, Radiation Oncology Services
  • Contact: Office of Clinical Research at 609-394-4130
GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery
Date added: Sep, 2024
  • Study Information: NCT05900037
  • Collaborator: GATT Technologies BV
  • Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, HPB Surgeon & Medical Director – Cancer Center
  • Contact: Office of Clinical Research at 609-394-4137

Gynecological Studies

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Date added: Sep, 2024
  • Study Information:NCT04251052
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Joyce Varughese, MD, FACOG, Medical Director, Center for Gynecologic Oncology
  • Contact: Office of Clinical Research at 609-394-4139

Lung Studies

SWOG S1827 (MAVERICK) TESTING WHETHER THE USE OF BRAIN SCANS ALONE INSTEAD OF BRAIN SCANS PLUS PREVENTIVE BRAIN RADIATION AFFECTS LIFESPAN IN PATIENTS WITH SMALL CELL LUNG CANCER
  • Study Information: NCT04155034; NCTN # S1827 (https://clinicaltrials.gov/ct2/show/NCT04155034)
  • Sponsor: Southwest Oncology Group
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Shirnett Williamson, MD, DABR, Radiation Oncologist, Director, Radiation Oncology Services
  • Contact: Office of Clinical Research at 609-394-4130
TESTING THE ADDITION OF RADIATION THERAPY TO THE USUAL IMMUNE THERAPY TREATMENT (ATEZOLIZUMAB) FOR EXTENSIVE STAGE SMALL CELL LUNG CANCER, THE RAPTOR TRIAL
  • Study Information: NCT04402788; NCTN #NRG-LU007 (https://clinicaltrials.gov/ct2/show/NCT04402788)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Khanh Nguyen, MD, MA, Radiation Oncologist
  • Contact: Office of Clinical Research at 609-394-4130

Gastro-Intestinal Studies

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
Date added: Sep, 2024
  • Study Information: NCT04949256
  • Collaborator: Merck Sharp & Dohme LLC
  • Principal investigator: Hongyan Liang, MD, PhD, Medical Oncologist
  • Contact: Office of Clinical Research at 609-394-4139

Other Studies

CANCER TISSUE BIOREPOSITORY
  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Krister Jones, MD, Pathologist, Chief, Cytopathology and Microbiology
  • Contact: Office of Clinical Research at 609-394-4130
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Date added: Sep, 2024
  • Study Information: NCT05334069
  • Collaborator: Alliance for Clinical Trials in Oncology
  • Principal Investigator: Hongyan Liang, MD, PhD, Medical Oncologist
  • Contact: Office of Clinical Research at 609-394-4139

Urogenital Studies

A Study of miRNA 371 in Patients With Germ Cell Tumors
Date added: Sep, 2024
  • Study Information: NCT04435756
  • Collaborator: SWOG Cancer Research Network
  • Principal Investigator: Charles Polotti, MD, Urologic Oncology Surgeon
  • Contact: Office of Clinical Research at 609-394-4139

Breast Studies

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
Date added: May, 2023
  • Study Information: NCT05568472/NCTN #S2010
  • Sponsor: SWOG Cancer Research Network
  • Collaborator: National Cancer Institute (NCI) 
  • Information provided by (Responsible Party): SWOG Cancer Research Network
  • Principal Investigator: Arturo Loaiza-Bonilla, MD, MDEd, FACP, Health System Director, Office of Clinical Research
  • Contact: Office of Clinical Research at 609-394-4130
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer EMBER-4
Date added: May, 2023
  • Study Information: NCT05514054
  • Sponsor: Eli Lilly and Company
  • Information provided by (Responsible Party): Eli Lilly and Company
  • Principal Investigator: Erica Linden, MD, Medical Director of Breast Oncology and Cancer Genetics
  • Contact: Office of Clinical Research at 609-394-4130
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Date added: Sep, 2024
  • Study Information: NCT04852887
  • Sponsor: NRG Oncology
  • Information provided by (Responsible Party): NRG Oncology
  • Principal Investigator: Nikhil Thaker, MD, MHA, MBA, PMP, CMQ, FABS, DABR, FAMIA, Medical Director, Radiation Oncology
  • Contact: Office of Clinical Research at 609-394-4133
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial
Date added: Sep, 2024
  • Study Information: NCT06216574
  • Sponsor: Wake Forest University Health Sciences
  • Information provided by (Responsible Party): Wake Forest University Health Sciences
  • Principal Investigator: Erica A. Linden, MD, Medical Director, Breast Oncology & Cancer Genetics
  • Contact: Office of Clinical Research at 609-394-4130

Other resources:

Accessibility by WAH
MAKE AN APPOINTMENT